This real-world multicenter study aimed to evaluate the efficacy and tolerability of the isatuximab, pomalidomide, and dexamethasone (IsaPd) combination in relapsed/refractory multiple myeloma (RRMM). Our results confirm the safety and efficacy of IsaPd, in line with findings from the pivotal ICARIA-MM clinical trial.
Martino, E.A., Derudas, D., Rossi, E., Terlizzi, S., Reddiconto, G., Stefanoni, P., et al. (2025). Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials. HAEMATOLOGICA, 110(4), 1028-1033 [10.3324/haematol.2024.286658].
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials
Gozzetti A.;
2025-01-01
Abstract
This real-world multicenter study aimed to evaluate the efficacy and tolerability of the isatuximab, pomalidomide, and dexamethasone (IsaPd) combination in relapsed/refractory multiple myeloma (RRMM). Our results confirm the safety and efficacy of IsaPd, in line with findings from the pivotal ICARIA-MM clinical trial.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Isatuximab pomalidomide and dexamethasone-Martino-2025.pdf
accesso aperto
Descrizione: Articolo
Tipologia:
PDF editoriale
Licenza:
Creative commons
Dimensione
3 MB
Formato
Adobe PDF
|
3 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/1317729